Merck Animal Health, a provider of animal health services, completed the acquisition of the aqua business of Elanco, an American pharmaceutical company which produces medicines and vaccinations for pets and livestock, for $1.3bn. “With the completion of this acquisition, we are well positioned within the aquaculture industry with a robust and comprehensive portfolio across warm water, cold water, vaccines, anti-parasitic treatments, water supplements and nutrition. We are excited to welcome our new colleagues to Merck Animal Health and we look forward to working together, driven by our common purpose of the Science of Healthier Animals®,” Rick DeLuca, Merck Animal Health President.